Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Preclinical toxicology profile of squalene epoxidase inhibitors.
Journal: Toxicology and applied pharmacology
Published: January 14, 2020
Phase 1 Single- and Multiple-Ascending-Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers.
Journal: Clinical pharmacology in drug development
Published: December 18, 2017
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.
Journal: ACS medicinal chemistry letters
Published: October 13, 2017
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.
Journal: Cancer discovery
Published: September 15, 2016
A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model.
Journal: Journal of inherited metabolic disease
Published: March 10, 2016
A mouse model of a human congenital disorder of glycosylation caused by loss of PMM2.
Journal: Human molecular genetics
Published: January 19, 2016
A brief overview of the 33rd Annual STP Symposium on the translational pathology: relevance of toxicologic pathology to human health.
Journal: Toxicologic pathology
Published: October 30, 2014
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
Journal: Science (New York, N.Y.)
Published: April 06, 2013
Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 22, 2011
Showing 1-11 of 11
Last Updated: 09/26/2026